These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33569305)

  • 1. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
    Pavan A; Bragadin AB; Calvetti L; Ferro A; Zulato E; Attili I; Nardo G; Dal Maso A; Frega S; Menin AG; Fassan M; Calabrese F; Pasello G; Guarneri V; Aprile G; Conte P; Rosell R; Indraccolo S; Bonanno L
    Transl Lung Cancer Res; 2021 Jan; 10(1):202-220. PubMed ID: 33569305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of
    Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and immune phenotypes associated with
    Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
    J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
    Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M
    Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
    Liang Y; Maeda O; Kondo C; Nishida K; Ando Y
    PLoS One; 2024; 19(7):e0307580. PubMed ID: 39037971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.
    Krishnamurthy N; Goodman AM; Barkauskas DA; Kurzrock R
    Eur J Cancer; 2021 May; 148():215-229. PubMed ID: 33744718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
    Torralvo J; Friedlaender A; Achard V; Addeo A
    Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Critical Review of the Prognostic and Predictive Implications of
    Manolakos P; Ward LD
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
    Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
    Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary Resistance to Immune Checkpoint Blockade in an
    Kwack WG; Shin SY; Lee SH
    Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.